R&D Pipeline
22 compounds matching your criteria
| Compound/indication | Phase 1 | Phase 2 | Phase 3 | Filed | |||
| Degludec Type 1 and 2 diabetes |  |
||||||
| DegludecPlus Type 1 and 2 diabetes | |
||||||
| rFXIII FXIII Congenital deficiency | |
||||||
| Liraglutide as anti-obesity agent Obesity |  |
||||||
| Turoctocog alfa Haemophilia A | |
||||||
| N9-GP (rFIX glycopegylated) Haemophilia B | |
||||||
| IDegLira Type 2 diabetes | |
||||||
| Vatreptacog alfa (rFVIIa) Haemophilia with inhibitors | |
||||||
| Anti-NKG2D Inflammation | |
||||||
| Anti-NKG2D Inflammation | |
||||||
| Anti-IL20 Inflammation | |
||||||
| Semaglutide Type 2 diabetes | |
||||||
| Liraglutide Depot Type 2 diabetes | |
||||||
| Anti-C5aR Inflammation | |
||||||
| NN1953 (Oral ins) Type 1 and 2 diabetes | |
||||||
| NN9924 (Oral GLP-1) Type 2 diabetes | |
||||||
| NN1218 (FIAsp) Type 1 and 2 diabetes | |
||||||
| N8-GP (rFVIII glycopegylated) Haemophilia A | |
||||||
| NN7415 (Anti-TFPI) Haemophilia A and B | |
||||||
| Anti-IL21 Inflammation | |
||||||
| Anti-NKG2A Inflammation | |
||||||
| NN8640 Growth disorder | |
||||||
